Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
The present study evaluated cellular and humoral immune parameters in myeloma patients, focusing on the effect of treatment and the risk of opportunistic infections. Peripheral blood lymphocyte subsets and serum levels of nonmyeloma immunoglobulins (Ig) were analysed in 480 blood samples from 77 mye...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1797054418551570432 |
|---|---|
| author | Schütt, P Brandhorst, D Stellberg, W Poser, M Ebeling, P Müller, S Buttkereit, U Opalka, B Lindemann, M Grosse-Wilde, H Seeber, S Moritz, T Nowrousian, MR |
| author_facet | Schütt, P Brandhorst, D Stellberg, W Poser, M Ebeling, P Müller, S Buttkereit, U Opalka, B Lindemann, M Grosse-Wilde, H Seeber, S Moritz, T Nowrousian, MR |
| author_sort | Schütt, P |
| collection | OXFORD |
| description | The present study evaluated cellular and humoral immune parameters in myeloma patients, focusing on the effect of treatment and the risk of opportunistic infections. Peripheral blood lymphocyte subsets and serum levels of nonmyeloma immunoglobulins (Ig) were analysed in 480 blood samples from 77 myeloma patients. Untreated myeloma patients exhibited significantly reduced CD4+/45RO+, CD19+, CD3+/HLA-DR+, and natural killer (NK) cells, as well as nonmyeloma IgA, IgG and IgM. Conventional-dose chemotherapy resulted in significantly reduced CD4+ and even further decline of CD4+/CD45RO+ and CD19+ cells, most notably in relapsed patients. Additional thalidomide treatment had no significant effects on these parameters. Following high-dose chemotherapy (HD-CTX), prolonged immunosuppression was observed. Although CD8+, NK, CD19+ and CD+/CD45RO+ cells recovered to normal values within 60, 90, 360 and 720 days, respectively, CD4+ counts remained reduced even thereafter. Nine opportunistic infections were observed, including five cytomegalovirus (CMV) diseases, one Pneumocystis carinii pneumonia (PCP) and three varicella zoster virus infections with CMV diseases and PCP occurring exclusively after HD-CTX. Opportunistic infections were correlated with severely reduced CD4+, as well as CD4+/CD45RO+ and CD19+ counts. Thus, myeloma patients display cellular and humoral immunodeficiencies, which increase following conventional as well as HD-CTX, and constitute an important predisposing factor for opportunistic infections. |
| first_indexed | 2024-03-06T18:57:01Z |
| format | Journal article |
| id | oxford-uuid:122e27e1-c375-4eaf-965c-63eaa741cf9b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:57:01Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:122e27e1-c375-4eaf-965c-63eaa741cf9b2022-03-26T10:06:27ZImmune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:122e27e1-c375-4eaf-965c-63eaa741cf9bEnglishSymplectic Elements at Oxford2006Schütt, PBrandhorst, DStellberg, WPoser, MEbeling, PMüller, SButtkereit, UOpalka, BLindemann, MGrosse-Wilde, HSeeber, SMoritz, TNowrousian, MRThe present study evaluated cellular and humoral immune parameters in myeloma patients, focusing on the effect of treatment and the risk of opportunistic infections. Peripheral blood lymphocyte subsets and serum levels of nonmyeloma immunoglobulins (Ig) were analysed in 480 blood samples from 77 myeloma patients. Untreated myeloma patients exhibited significantly reduced CD4+/45RO+, CD19+, CD3+/HLA-DR+, and natural killer (NK) cells, as well as nonmyeloma IgA, IgG and IgM. Conventional-dose chemotherapy resulted in significantly reduced CD4+ and even further decline of CD4+/CD45RO+ and CD19+ cells, most notably in relapsed patients. Additional thalidomide treatment had no significant effects on these parameters. Following high-dose chemotherapy (HD-CTX), prolonged immunosuppression was observed. Although CD8+, NK, CD19+ and CD+/CD45RO+ cells recovered to normal values within 60, 90, 360 and 720 days, respectively, CD4+ counts remained reduced even thereafter. Nine opportunistic infections were observed, including five cytomegalovirus (CMV) diseases, one Pneumocystis carinii pneumonia (PCP) and three varicella zoster virus infections with CMV diseases and PCP occurring exclusively after HD-CTX. Opportunistic infections were correlated with severely reduced CD4+, as well as CD4+/CD45RO+ and CD19+ counts. Thus, myeloma patients display cellular and humoral immunodeficiencies, which increase following conventional as well as HD-CTX, and constitute an important predisposing factor for opportunistic infections. |
| spellingShingle | Schütt, P Brandhorst, D Stellberg, W Poser, M Ebeling, P Müller, S Buttkereit, U Opalka, B Lindemann, M Grosse-Wilde, H Seeber, S Moritz, T Nowrousian, MR Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. |
| title | Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. |
| title_full | Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. |
| title_fullStr | Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. |
| title_full_unstemmed | Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. |
| title_short | Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. |
| title_sort | immune parameters in multiple myeloma patients influence of treatment and correlation with opportunistic infections |
| work_keys_str_mv | AT schuttp immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT brandhorstd immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT stellbergw immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT poserm immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT ebelingp immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT mullers immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT buttkereitu immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT opalkab immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT lindemannm immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT grossewildeh immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT seebers immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT moritzt immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections AT nowrousianmr immuneparametersinmultiplemyelomapatientsinfluenceoftreatmentandcorrelationwithopportunisticinfections |